Skip to main content

Table 4 Positive rates for disease-specific antibodies in patients with LAM testing positive for ANA and controlsa

From: Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study

 

Our study

Hayashi [22]

p-value

Participants

Patients with LAM

Healthy women

 

Number of Participants

41 †

446

–

Anti-RNP antibody

6.5% (2/31)

2.2% (10/446)

0.18 ‡

Anti-Sm antibody

0% (0/31)

0% (0/446)

1.0 ‡

Anti-SS-A antibody

14.7% (5/34)

11.2% (50/446)

0.57 ‡

Anti-SS-B antibody

2.9% (1/34)

0.90% (4/446)

0.31 ‡

Anti-Scl-70 antibody

0% (0/32)

0% (0/446)

1.0 ‡

Anti-Jo-1 antibody

0% (0/30)

0% (0/446)

1.0 ‡

Anti-centromere antibody

0% (0/19)

5.8% (26/446)

0.62 ‡

Anti-dsDNA antibody

6.5% (2/31)

1.3% (6/446)

0.09 ‡

  1. aIn healthy subjects, the positive rate of the disease-specific antibodies was only analysed for positive cases of ANA in the previous study [22]. Thus, only cases with positive ANA at dilutions of 1:40 or higher were analysed
  2. †Forty-one patients with LAM were ANA-positive at dilutions of 1:40 or higher in this study
  3. ‡Fisher’s exact test
  4. Abbreviations: ANA anti-nuclear antibody, RNP U1-ribonucleoprotein, SS-A Ro, SS-B La, Scl-70 topoisomerase, Jo-1 histidyl-tRNA synthetase, dsDNA double-stranded DNA
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172